Explore our materials

European Meeting on HIV & Hepatitis 2019

First-Line Therapies: Implications for Long-Term Resistance - Anne-Genevieve Marcelin, PharmD, Phd

European Meeting on HIV & Hepatitis 2019

First Day Treatment Initiation - Tristan Barber, MA, MRCP

European Meeting on HIV & Hepatitis 2019

What's in the Pipeline? Presentations from the Industry: Janssen - Hanneke Schuitemaker, PhD

Kathleen Squires

European Meeting on HIV & Hepatitis 2019

What's in the Pipeline? Presentations from the Industry: Merck - Kathleen Squires, MD

European Meeting on HIV & Hepatitis 2019

What's in the Pipeline? Presentations from the Industry: ViiV - Harmony Phillips Garges, MD, MPH

European Meeting on HIV & Hepatitis 2019

New Approaches to STI Management - Gary Whitlock, MD

Roger Paredes

MD, PhD

European Meeting on HIV & Hepatitis 2019

Genetic Barrier: Clinical Cases - Roger Paredes, MD, PhD

CFP

Carlo Federico Perno

MD, PhD

European Meeting on HIV & Hepatitis 2019

How Does the Reservoir Influence the Clinician's Decisions? - Carlo Frederico Perno, MD, PhD

Anne-Geneviève Marcelin

European Meeting on HIV & Hepatitis 2019

Resistance to Integrase Inhibitors - Anne-Genevieve Marcelin, PharmD, PhD

Ravindra Gupta

MA, MPH, BMBCh, PhD, FRCP, FRCPath, FMedSci

European Meeting on HIV & Hepatitis 2019

Top 10 Important Observations of the Last Year Affecting Clinical Management - Ravindra Gupta, MD, PhD

RSV

APACC 2019

Provider’s perspective of PrEP demedicalization

RSV